AK129

anti-PD-1 and LAG-3 bispecific antibody · Akeso Biopharma

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for AK129, covering 2024-09-19 to 2025-06-03. Get the full timeline:

Most recent: Clinical Trial Update: AK129 Combination Therapy for Advanced Solid Tumors [Phase 1, Phase 2]